These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11794142)

  • 1. Angiotensin-converting enzyme inhibitors for the prevention and treatment of cardiovascular disease.
    Frishman WH
    Heart Dis; 2000; 2(3):183-4. PubMed ID: 11794142
    [No Abstract]   [Full Text] [Related]  

  • 2. Controversies in antiplatelet therapy for patients with cardiovascular disease.
    Bates ER; Lau WC
    Circulation; 2005 May; 111(17):e267-71. PubMed ID: 15867186
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
    Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B
    Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of aspirin in patients taking angiotensin converting enzyme inhibitors].
    Altin T; Kiliçkap M
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():14-9. PubMed ID: 18160362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [20 years of cardiovascular epidemiology. The clinician's viewpoint].
    Bertrand ME
    Rev Epidemiol Sante Publique; 1996 Nov; 44(6):556-62. PubMed ID: 9005491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacologic prevention of cardiovascular diseases--2005].
    Kancz S
    Orv Hetil; 2005 May; 146(20 Suppl 2):1122-31. PubMed ID: 15945241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Which interactions are there for equal doses of acetylsalicylic acid and ACE inhibitors?].
    Joost HG
    Dtsch Med Wochenschr; 2003 Feb; 128(8):398. PubMed ID: 12594628
    [No Abstract]   [Full Text] [Related]  

  • 8. Canadian Hypertension Education Program. Brief overview of 2004 recommendations.
    Campbell N;
    Can Fam Physician; 2004 Oct; 50():1411-5. PubMed ID: 15526879
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular risk in patients with type 2 diabetes.
    Shanks M; Holmes DT; Cermakova L; Frohlich J
    CMAJ; 2005 Apr; 172(9):1160-1. PubMed ID: 15851694
    [No Abstract]   [Full Text] [Related]  

  • 10. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy.
    Tsang JL; Mendelsohn A; Tan MK; Hackam DG; Leiter LA; Fitchett D; Lin PJ; Grima E; Langer A; Goodman SG;
    Am J Cardiol; 2008 Nov; 102(9):1142-5. PubMed ID: 18940280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The "clopidogrel resistance" trap.
    Serebruany VL
    Am J Cardiol; 2007 Sep; 100(6):1044-6. PubMed ID: 17826395
    [No Abstract]   [Full Text] [Related]  

  • 14. A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
    Rastegarpanah M; Malekzadeh F; Thomas GN; Mohagheghi A; Cheng KK; Marshall T
    Arch Iran Med; 2008 May; 11(3):306-13. PubMed ID: 18426322
    [No Abstract]   [Full Text] [Related]  

  • 15. North American perspective of antiplatelet agents.
    Gorelick PB
    Adv Neurol; 2003; 92():281-91. PubMed ID: 12760195
    [No Abstract]   [Full Text] [Related]  

  • 16. President's page: the promise of prevention: so, why aren't all cardiologists "preventive"?
    Wolk MJ; Bairey Merz CN; Thompson PD
    J Am Coll Cardiol; 2004 Nov; 44(10):2082-4. PubMed ID: 15542296
    [No Abstract]   [Full Text] [Related]  

  • 17. A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):547-50. PubMed ID: 27062678
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?
    Cleland JG
    Nat Clin Pract Cardiovasc Med; 2006 May; 3(5):234-5. PubMed ID: 16645645
    [No Abstract]   [Full Text] [Related]  

  • 19. Secondary prevention of ischaemic cardiac events.
    Gami A
    Clin Evid; 2006 Jun; (15):195-228. PubMed ID: 16973010
    [No Abstract]   [Full Text] [Related]  

  • 20. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.